text
"['\n1. 요약재무정보\n당사는 국제회계기준을 채택하여 제정한 한국채택국제회계기준을 최초 도입하였습니다. 당사의 한국채택국제회계기준으로의 전환일은 2010년 01월 01일이며, 한국채택국제회계기준 채택일은 2011년 01월 01일입니다.\n가. 요약 연결 재무제표* 삼성제약(주)와 그 종속기업(연결) (단위 : 원)\n\u3000\n제 66 기 3분기말\n제 65 기말\n자산\n\u3000\n\u3000\n\u3000유동자산\n52,334,310,555\n79,724,616,717\n\u3000\u3000현금및현금성자산\n2,057,252,781\n3,151,357,753\n\u3000\u3000단기금융상품\n1,200,000,000\n1,200,000,000\n\u3000\u3000매출채권\n15,862,113,473\n16,699,562,155\n\u3000\u3000기타유동채권\n12,682,796,344\n16,688,725,138\n\u3000\u3000단기매매금융자산\n7,734,731,862\n3,816,549,555\n\u3000\u3000기타유동금융자산\n230,594,800\n25,247,161,400\n\u3000\u3000기타유동자산\n544,457,593\n540,227,493\n\u3000\u3000재고자산\n12,022,363,702\n9,308,654,877\n\u3000\u3000매각예정 자산\n\u3000\n3,072,378,346\n\u3000비유동자산\n106,316,608,729\n80,922,047,065\n\u3000\u3000유형자산\n78,135,758,501\n73,435,190,787\n\u3000\u3000무형자산\n3,769,571,115\n3,229,294,090\n\u3000\u3000기타비유동채권\n2,072,100,000\n3,232,400,000\n\u3000\u3000기타비유동금융자산\n21,453,120,925\n\u3000\n\u3000\u3000관계기업에 대한 투자자산\n816,058,188\n955,162,188\n\u3000\u3000투자부동산 및 기타투자자산\n70,000,000\n70,000,000\n\u3000자산총계\n158,650,919,284\n160,646,663,782\n부채\n\u3000\n\u3000\n\u3000유동부채\n22,032,456,444\n24,693,164,014\n\u3000\u3000매입채무\n6,082,372,609\n4,692,343,679\n\u3000\u3000단기차입금\n10,520,000,000\n11,152,000,000\n\u3000\u3000유동성장기차입금\n957,960,000\n957,960,000\n\u3000\u3000유동성사채\n1,202,966,246\n4,200,675,190\n\u3000\u3000기타유동채무\n3,269,157,589\n3,687,596,385\n\u3000\u3000미지급법인세\n\u3000\n2,588,760\n\u3000비유동부채\n2,611,291,520\n4,290,522,616\n\u3000\u3000장기차입금\n1,421,767,830\n2,149,737,670\n\u3000\u3000기타비유동금융부채\n105,290,000\n155,290,000\n\u3000\u3000퇴직급여채무\n804,174,077\n1,525,334,223\n\u3000\u3000비유동계약부채\n280,059,613\n460,160,723\n\u3000부채총계\n24,643,747,964\n28,983,686,630\n자본\n\u3000\n\u3000\n\u3000지배기업의 소유주에게 귀속되는 자본\n134,007,171,320\n131,662,977,152\n\u3000\u3000자본금\n29,305,563,500\n29,117,523,500\n\u3000\u3000\u3000보통주자본금\n29,305,563,500\n29,117,523,500\n\u3000\u3000자본잉여금\n83,078,197,972\n82,305,312,594\n\u3000\u3000기타자본조정\n(991,206,478)\n(991,206,478)\n\u3000\u3000기타포괄손익누계액\n27,122,677,259\n24,610,931,430\n\u3000\u3000이익잉여금(결손금)\n(4,508,060,933)\n(3,379,583,894)\n\u3000자본총계\n134,007,171,320\n131,662,977,152\n자본과부채총계\n158,650,919,284\n160,646,663,782\n제 66(당) 3분기\n제 65(전) 3분기\n과\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 목\n3개월\n누적\n3개월\n누적\n매출액\n23,336,104,259\n33,357,543,773\n10,478,595,665\n35,186,916,482\n매출총이익\n4,892,045,714\n7,753,329,741\n1,455,102,505\n8,307,408,026\n영업이익(손실)\n(3,365,864,536)\n(4,296,659,634)\n(1,976,405,414)\n(1,877,691,287)\n법인세비용차감전순이익(손실)\n(6,342,709,183)\n(1,128,477,039)\n718,140,915\n2,754,609,916\n당기순이익(손실)\n(6,342,709,183)\n(1,128,477,039)\n718,140,915\n2,754,609,916\n기타포괄손익\n2,511,745,829\n2,511,745,829\n\u3000\n72,797,510\n총포괄손익\n(3,830,963,354)\n1,383,268,790\n718,140,915\n2,827,407,426\n주당이익\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000기본주당이익(손실)\xa0\n(108)\n(19)\n16\n56\n[( )는 부(-)의 수치임]※ 제65기 연결재무제표는 한국채택국제회계기준 작성기준에 따라 작성되었으며 외부감사인의 감사 및 검토를 마친 재무제표입니다.※ 제66기 3분기 연결 재무제표는 한국채택국제회계기준 작성기준에 따라 작성되었습니다.\n나. 연결재무제표의 연결에 포함된 회사\n사업연도\n연결에 포함된 회사명\n전기대비 연결에추가된 회사명\n전기대비 연결에서제외된 회사명\n제66기3분기\n삼성제약헬스케어(주)\n-\n-\n- 2014년 12월 01일 삼성제약(주)에서 1억원을 출자하여 삼성제약헬스케어(주)설립(기준일 현재 기준 삼성제약(주) 지분율100%)하였음다. 요약 재무정보 (별도)* 삼성제약(주)\xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0 \xa0\xa0 (단위 : 원)\n\u3000\n제 66 기 3분기말\n제 65 기말\n자산\n\u3000\n\u3000\n\u3000유동자산\n51,386,413,555\n79,680,789,054\n\u3000\u3000현금및현금성자산\n999,678,942\n2,813,649,305\n\u3000\u3000단기금융상품\n1,200,000,000\n1,200,000,000\n\u3000\u3000기타금융자산\n7,965,326,662\n29,063,710,955\n\u3000\u3000매출채권\n14,598,080,458\n15,997,486,101\n\u3000\u3000기타 채권\n14,191,309,254\n18,206,403,847\n\u3000\u3000재고자산\n11,898,513,884\n8,788,084,869\n\u3000\u3000기타유동자산\n533,504,355\n539,075,631\n\u3000\u3000매각예정 자산\n\u3000\n3,072,378,346\n\u3000비유동자산\n107,189,564,421\n81,302,242,263\n\u3000\u3000기타비유동금융자산\n816,058,188\n955,162,188\n\u3000\u3000기타채권\n2,002,100,000\n3,132,400,000\n\u3000\u3000유형자산\n78,126,955,142\n73,417,379,317\n\u3000\u3000투자부동산 및 기타투자자산\n70,000,000\n70,000,000\n\u3000\u3000무형자산\n3,767,184,461\n3,227,300,758\n\u3000\u3000종속기업 및 관계기업 투자 자산\n22,407,266,630\n500,000,000\n\u3000자산총계\n158,575,977,976\n160,983,031,317\n부채\n\u3000\n\u3000\n\u3000유동부채\n20,750,558,370\n23,701,252,165\n\u3000\u3000매입채무\n5,017,423,037\n3,885,293,953\n\u3000\u3000유동성회사채\n1,202,966,246\n4,200,675,190\n\u3000\u3000기타유동채무\n3,052,209,087\n3,597,323,022\n\u3000\u3000단기차입금\n10,520,000,000\n11,060,000,000\n\u3000\u3000유동성장기차입금\n957,960,000\n957,960,000\n\u3000비유동부채\n2,517,441,058\n4,219,547,733\n\u3000\u3000장기차입금\n1,421,767,830\n2,149,737,670\n\u3000\u3000퇴직급여채무\n710,323,615\n1,454,359,340\n\u3000\u3000기타비유동금융부채\n233,707,155\n155,290,000\n\u3000\u3000비유동계약부채\n151,642,458\n460,160,723\n\u3000부채총계\n23,267,999,428\n27,920,799,898\n자본\n\u3000\n\u3000\n\u3000자본금\n29,305,563,500\n29,117,523,500\n\u3000자본잉여금\n83,078,205,383\n82,305,320,005\n\u3000기타자본조정\n(991,206,478)\n(991,206,478)\n\u3000기타포괄손익누계액\n27,267,087,960\n24,610,931,430\n\u3000이익잉여금(결손금)\n(3,351,671,817)\n(1,980,337,038)\n\u3000자본총계\n135,307,978,548\n133,062,231,419\n자본과부채총계\n158,575,977,976\n160,983,031,317\n종속 관계 공동기업 투자주식의 평가방법\n원가법\n원가법\n\u3000\n제 66 기 3분기\n제 65 기 3분기\n3개월\n누적\n3개월\n누적\n매출액\n10,903,798,132\n31,156,376,727\n9,833,198,727\n31,929,292,225\n매출총이익\n1,938,472,128\n6,100,879,279\n900,689,403\n6,273,529,954\n영업이익(손실)\n(2,181,502,012)\n(4,852,340,175)\n(2,125,594,068)\n(1,303,895,504)\n법인세비용차감전순이익(손실)\n(6,249,431,340)\n(1,371,334,779)\n591,140,488\n3,386,531,681\n당기순이익(손실)\n(6,249,431,340)\n(1,371,334,779)\n591,140,488\n3,386,531,681\n기타포괄손익\n2,656,156,530\n2,656,156,530\n\u3000\n\u3000\n총포괄손익\n(3,593,274,810)\n1,284,821,751\n591,140,488\n3,386,531,681\n주당이익\n\u3000\n\u3000\n\u3000\n\u3000\n\u3000기본주당이익(손실)\xa0\n(107)\n(23)\n14\n69\n[( )는 부(-)의 수치임]※ 제65기 별도재무제표는 한국채택국제회계기준 작성기준에 따라 작성되었으며 외부감사인의 감사 및 검토를 마친 재무제표입니다.※ 제66기 3분기 별도재무제표는 한국채택국제회계기준 작성기준에 따라 작성되었습니다.\n']"
